Edge Rewrite
// HTMLRewriter · presentation

This page was redesigned at the edge.

Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.

// request.cf · coarse context

A page that knows where it met you.

Only coarse request metadata is shown. This demo does not display or persist visitor IP addresses.

Country
US
Cloudflare location
CMH
Connection
HTTP/2
Language
Not provided

Ray ID: a22b08524cb55aae

Jump to content

Isotodesnitazene

From Wikipedia, the free encyclopedia

Isotodesnitazene
Identifiers
  • 2-[(4-isopropoxyphenyl)methyl]-1-(2-diethylaminoethyl)benzimidazole
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC23H31N3O
Molar mass365.521 g·mol−1
3D model (JSmol)
  • CCN(CC)CCN1C2=CC=CC=C2N=C1CC3=CC=C(C=C3)OC(C)C
  • InChI=1S/C23H31N3O/c1-5-25(6-2)15-16-26-22-10-8-7-9-21(22)24-23(26)17-19-11-13-20(14-12-19)27-18(3)4/h7-14,18H,5-6,15-17H2,1-4H3
  • Key:MXCQZQAWFBUAJT-UHFFFAOYSA-N

Isotodesnitazene is a benzimidazole derivative which has potent opioid effects, having approximately 75x the potency of morphine. While isotodesnitazene itself appears to have been only rarely sold as a designer drug, numerous closely related compounds such as metodesnitazene, etodesnitazene, protodesnitazene, butodesnitazene, isotonitazene, isotonitazepyne and isotocyanozene have all been sold on the illicit market, so the pharmacological and analytical properties of isotodesnitazene have also been studied in the expectation that it may similarly become prominent at some point.[1][2][3][4][5][6]

See also

[edit]

References

[edit]
  1. Taoussi O, Berardinelli D, Zaami S, Tavoletta F, Basile G, Kronstrand R, et al. (July 2024). "Human metabolism of four synthetic benzimidazole opioids: isotonitazene, metonitazene, etodesnitazene, and metodesnitazene". Archives of Toxicology. 98 (7): 2101–2116. Bibcode:2024ArTox..98.2101T. doi:10.1007/s00204-024-03735-0. PMC 11169013. PMID 38582802.
  2. De Vrieze LM, Stove CP, Vandeputte MM (August 2024). "Nitazene test strips: a laboratory evaluation". Harm Reduction Journal. 21 (1) 159. doi:10.1186/s12954-024-01078-8. PMC 11350930. PMID 39198843.
  3. Gatch MB, Hill RD, Sundar M, Shetty RA (July 2025). "Discriminative stimulus and antinociceptive effects of sixteen nitazene analogs in rodents". Neuropharmacology. 272 110416. doi:10.1016/j.neuropharm.2025.110416. PMID 40120927.
  4. Wachełko O, Tusiewicz K, Szpot P, Zawadzki M (August 2025). "The UHPLC-MS/MS method for the determination of 26 synthetic benzimidazole opioids (nitazene analogs) with isomers separation". Journal of Pharmaceutical and Biomedical Analysis. 260 116796. doi:10.1016/j.jpba.2025.116796. PMID 40068235.
  5. Hardwick EK, Couch AN, Davidson JT (March 2026). "Comparison of Activation Techniques for the Identification of Nitazene Analogs Using the NIST/NIJ Data Interpretation Tool". Rapid Communications in Mass Spectrometry. 40 (5) e70004. doi:10.1002/rcm.70004. PMID 41359886.
  6. Man N, Chrzanowska A, Sutherland R, Sadaphale V, Barratt M, Bruno R, et al. (2025). Availability of nitazenes for purchase in Australia and internationally via cryptomarkets, September 2021 - August 2025 (Report). UNSW Sydney. doi:10.26190/unsworks/31698.